본문으로 건너뛰기
← 뒤로

NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.

1/5 보강
Journal of the National Comprehensive Cancer Network : JNCCN 📖 저널 OA 5.7% 2022: 0/1 OA 2023: 2/2 OA 2024: 1/4 OA 2025: 2/32 OA 2026: 1/67 OA 2022~2026 2025 Vol.23(12) p. 498-506
Retraction 확인
출처

von Mehren M, Kane JM, Armstrong SA, Balach T, Bishop AJ, Buehler D

📝 환자 설명용 한 줄

The treatment landscape for soft tissue sarcomas (STS) is evolving constantly.

이 논문을 인용하기

↓ .bib ↓ .ris
APA von Mehren M, Kane JM, et al. (2025). NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.. Journal of the National Comprehensive Cancer Network : JNCCN, 23(12), 498-506. https://doi.org/10.6004/jnccn.2025.0058
MLA von Mehren M, et al.. "NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025.." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 23, no. 12, 2025, pp. 498-506.
PMID 41671462 ↗

Abstract

The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반